Cardiometabolic aspects of polycystic ovarian syndrome by Cho, Li Wei et al.
Vascular Health and Risk Management 2007:3(1) 55–63
© 2007 Dove Medical Press Limited.  All rights reserved
55
R E V I E W
Cardiometabolic aspects of polycystic ovarian 
syndrome
Li Wei Cho1 
Harpal S Randeva2  
Stephen L Atkin1
1Department of Medicine, University 
of Hull; 2Metabolic Unit, University 
Hospitals Coventry & Warwickshire 
NHS Trust, UK
Correspondence: Li Wei Cho  
Michael White Centre for Diabetes and 
Endocrinology, Hull Royal Inﬁrmary, 220-
236 Anlaby Road, Hull, HU3 2RW, UK 
Tel +44 1482 675371  
Fax +44 1482 675395 
Email l.cho@hull.ac.uk
A
U
T
H
O
R
 
C
O
P
Y
.
N
o
t
 
f
o
r
 
p
u
b
l
i
c
a
t
i
o
n
Abstract: It is estimated that 6%–7% of women of reproductive age have polycystic ovarian 
syndrome (PCOS). Women with this condition exhibit an adverse cardiovascular risk proﬁle, 
characteristic of the cardiometabolic syndrome and given the high prevalence of PCOS in the 
female population, this condition may contribute towards the acceleration of cardiovascular 
disease among young women. This article summarizes the recent development and ﬁndings in 
the cardiometabolic abnormalities in patients with PCOS. Patients with PCOS have the clinical 
features of oligomenorrhoea, hirsutism and infertility; however, they also exhibit hyperinsu-
linemia, obesity, hypertension, dyslipidemia, and an increased pro-thrombotic state. They have 
an increased risk of type 2 diabetes and impaired glucose tolerance, and sleep apnea is also found 
more commonly in this population. However, despite the presence of cardiovascular risk factors 
and increased surrogate markers of cardiovascular disease it is unclear if they have accelerated 
atherosclerosis. End point studies are currently lacking and the available evidence are conﬂicting. 
Adipose tissue has emerged as an important endocrine organ over the last decade and gained 
recognition in having an important role in the cardiometabolic syndrome. Adiponectin that is 
secreted exclusively by adipocytes has recently been recognized as an important marker of 
cardiometabolic syndrome, obesity, type 2 diabetes, and coronary artery disease. Other adipo-
cytokines like leptin and resistin have also recently been recognized. This article will address 
the current evidence for the adverse cardiovascular risk in PCOS and the other factors that may 
be implicated. Finally the therapeutic options for treatment will be discussed. 
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Introduction
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting 
6%–7% of the population (Knochenhauer et al 1998; Diamanti-Kandarakis et al 1999; 
Asuncion et al 2000; Azziz et al 2004). It is characterized by chronic anovulation 
and hyperandrogenism with the clinical manifestation of oligomenorrhoea, hirsut-
ism, and acne (Franks 1995). In January 2004, the European Society for Human 
Reproduction and Embryology (ESHRE) and the American Society for Reproductive 
Medicine (ASRM) co-sponsored the Rotterdam polycystic ovary syndrome consensus 
workshop that published diagnostic guidelines, building on the consensus statement 
of the National Institutes of Health 1990 (ESHRE/ASRM-Sponsored_PCOS_Con-
sensus_Workshop_Group 2004). The Rotterdam criteria for the diagnosis of PCOS 
states 2 of the 3 features needs to be present to make the diagnosis and with the exclu-
sion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, 
Cushing’s syndrome). These features includes (1) Oligo- or anovulation (2) Clinical 
and/or biochemical signs of hyperandrogenism and (3) Polycystic ovaries (either 12 
or more follicles measuring 2–9 mm in diameter, or an ovarian volume of >10 cm3) 
(Balen et al 2003).Vascular Health and Risk Management 2007:3(1)  56
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It has now been recognized that the diagnosis of metabolic 
syndrome identiﬁes patients at increased risk of developing 
cardiovascular disease, and attempts have been made to de-
velop the most convenient and useful criteria for the diagnosis 
of this condition in clinical practice. With the pathogenesis of 
metabolic syndrome not well understood, central obesity and 
insulin resistance are acknowledged as important causative 
factors (Anderson et al 2001; Carr et al 2004; Nesto 2003). 
The most recent International Diabetes Federation consensus, 
however, has developed a new deﬁnition emphasizing the 
importance of central obesity with modiﬁcations according 
to ethnic groups (Alberti et al 2006). Previous deﬁnitions 
from the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP III), USA (NCEP/ATPIII 
2001) and the World Health Organization (WHO) had 
emphasized insulin resistance (Alberti and Zimmet 1998; 
Grundy et al 2004).
It would appear that many women with PCOS fulﬁl 
the criteria for the metabolic syndrome in view of a higher 
reported incidence of hypertension, dyslipidemia, visceral 
obesity, insulin resistance and hyperinsulinemia in this 
population (Glueck et al 2003). It is recognized that insulin 
resistance and compensatory hyperinsulinemia not only 
contribute to hyperglycemia, but they also have a pathophysi-
ological role in the development of the cardio-metabolic state 
(Mather et al 2000).
Metabolic abnormalities of PCOS
Hyperinsulinemia and insulin resistance
Insulin binds to its receptor on the cell membrane facilitating 
the delivery of glucose across the membrane by enhancing 
the expression of GLUT transporters (Stephens and Pilch 
1995). Disturbance in insulin’s ability to bind to its receptor, 
or the transport mechanism across the cell membrane may 
lead to a state of reduced sensitivity to insulin, or insulin 
resistance. Studies suggest that insulin induced receptor 
autophosphorylation is markedly diminished in approxi-
mately 50% of PCOS women. In those PCOS women who 
have normal receptor autophosphorylation, it remains likely 
that signalling mechanism downstream of the receptor are 
abnormal (Dunaif 1995). In addition to decreased insulin 
sensitivity, pancreatic β-cell secretory dysfunction has also 
been reported (Ehrmann et al 1995; Dunaif and Finegood 
1996). Furthermore, a reduction in hepatic insulin extraction 
resulting in a reduction of insulin clearance rate may also 
contribute to the high insulin levels (Mahabeer et al 1989; 
O’Meara et al 1993).
Insulin stimulates lipogenesis in arterial tissue and adi-
pose tissue via an increased production of acetyl-Co A, and 
the entry of glucose and triglycerides (Pekala et al 1983). 
Dyslipidemia associated with high levels of triglycerides and 
low levels of HDL cholesterol in cardiometabolic syndrome 
are attributed to the effect of insulin on cholesterol ester 
transfer protein that promotes the transfer of cholesterol from 
HDL to VLDL and resultant catabolism of Apo lipoprotein 
A (Swenson 1991; Chen et al 1991). As insulin increases the 
levels of HMG Co A reductase, the rate-limiting enzyme in 
the synthesis of cholesterol, it may contribute to the raised 
cholesterol level that is also a feature of hyperinsulinemia 
(Dietschy and Brown 1974).
Loss of peroxisome proliferator activated nuclear recep-
tor (PPAR) gamma has been linked to the development of 
severe insulin resistance, diabetes, and hypertension (Celi 
and Shuldiner 2002). Although both metformin and the 
thiazolidinediones act as insulin sensitizers, one recent 
study suggested that only rosiglitazone, but not metformin, 
increased the expression of PPAR gamma in peripheral tis-
sue (Tiikkainen et al 2004) thereby increasing peripheral 
insulin sensitivity. This may suggest that the thiazolidin-
ediones may have additional peripheral beneﬁts compared 
with metformin.
Visceral obesity
The prevalence of obesity in PCOS varies widely, between 
approximately 10–50% (Balen et al 1995; Carmina et al 
1992). Obese PCOS have lower levels of luteinizing hormone 
(LH), sex hormone binding globulin (SHBG), dehydroepi-
androsterone (DHEAS), dihydrotestosterone, free insulin-like 
growth Factor (IGF)-I, high-density lipoprotein, and higher 
low-density lipoprotein, compared with the nonobese PCOS 
group (Silfen et al 2003). However, the situation is complex; 
not all obese people are insulin resistant and not all who are 
insulin resistant are obese. Gluteo-femoral obesity is less 
associated with insulin resistance than is central or android 
obesity (Basdevant et al 1987). A state of hyperinsulinemia 
may itself contribute to obesity by the anabolic effect on fat 
metabolism through adipogenesis with increased uptake of 
glucose into adipocytes, the production of triglycerides and 
inhibition of hormone sensitive lipase (Arner 2005).
Hypertension 
Hyperinsulinemia may contribute to the hypertension of the 
cardiometabolic syndrome by enhanced sodium retention 
(Zavaroni et al 1995), causing an increased intracellular 
sodium and calcium (Resnick 1992), and stimulation of the Vascular Health and Risk Management 2007:3(1)  57
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sympathetic nervous system (Muller-Wieland et al 1998; 
Sechi and Bartoli 1996).
Insulin also stimulates the release of IGF-1 that may 
contribute to the development of hypertension by causing 
vascular smooth muscle hypertrophy. Current evidence 
on prevalence of hypertension in patients with PCOS are 
conﬂicting at present with some studies suggesting a higher 
prevalence in this population (Vrbikova et al 2003; Elting 
et al 2001; Orbetzova et al 2003; Holte et al 1996), but not by 
others (Cibula et al 2000; Zimmermann et al 1992; Sampson 
et al 1996). A large long-term follow-up study by Wild et al 
(2000a) suggested an increased prevalence of hypertension in 
patients with PCOS, but with no increased risk of mortality 
and morbidity from coronary heart disease.
Dyslipidemia
Data are conﬂicting on whether women with PCOS have a 
characteristic dyslipidemia. Studies have reported decreased 
levels of the cardioprotective high-density cholesterol 
lipoprotein (HDL-C), and elevated levels of triglycerides 
(Reaven 1988; Robinson et al 1996; Conway et al 1992; 
Holte et al 1994; Wild et al 1985; Legro et al 1999), although 
in one study HDL was elevated (Legro et al 2001). Of con-
cern, dyslipidemia has been found at puberty in studies on 
adolescent girls with a history of premature pubarche (Kent 
and Legro 2002) and the metabolic disturbances can often 
be detected in the prepubertal period and throughout puberty 
(Ibanez et al 1998). This dyslipidemia is seen in both lean 
and obese PCOS (Yildirim et al 2003)
Pro-thrombotic state
Hyperinsulinemia contributes to the prothrombotic state by 
reducing ﬁbrinolysis and raising the level of plasminogen 
activator inhibitor (PAI-1) (Potter van Loon et al 1993). 
In patients with PCOS, the level of PAI-1 was found to be 
elevated (Atiomo et al 1998; Sampson et al 1996; Yildiz 
et al 2002), and it decreased with improvement in insulin 
sensitivity, either through weight loss (Andersen et al 1995) 
or the use of insulin sensitizing agents (Ehrmann et al 1997; 
Velazquez et al 1997). The increase in PAI-1 activity in 
PCOS was thought to be independent of body mass index 
since elevated levels were also observed in lean PCOS 
women. Moreover, the increased level of PAI activity in 
PCOS was directly correlated with insulin resistance, thus 
implicating it as a contributing cardiovascular risk factor 
(Tarkun et al 2004). However, other studies disagree (Atiomo 
et al 2000; Dahlgren et al 1994).
Risk of type 2 diabetes 
PCOS is commonly detected in a younger age group and is 
associated with a high risk of progression to type 2 diabetes 
and impaired glucose tolerance. For example, in one study, 
35% of patients with PCOS had impaired glucose tolerance 
and 10% had type 2 diabetes by the age of 40 (Ehrmann et al 
1999). A history of type 2 diabetes in a ﬁrst-degree relative 
appears to deﬁne a subset of PCOS subjects with a greater 
prevalence of insulin secretory defects. The risk of develop-
ing type 2 diabetes through increased insulin resistance in 
PCOS may be enhanced by the defects described in insulin 
secretion (Ehrmann et al 1995).
A unique defect in serine phosphorylation of the insulin 
receptor that resulted in decreased activation of the recep-
tor has been identiﬁed in about 50% of women with PCOS 
(Zhang et al 1995). Furthermore, serine phosphorylation of 
CYP17 (Cytochrome P450, subfamily XVII), may also be 
part of the mechanism of increased adrenal androgen synthesis 
implicating serine phosphorylation an important process in the 
PCOS phenotype. The CYP17 gene encodes the cytochrome 
P450c17 enzyme which mediates the 17α-hydroxylation of 
pregnenolone and progesterone, and subsequent conversion 
of these 17-hydroxylated products to the estradiol precursors 
DHEA and androstenedione. In addition, familial PCOS has 
been linked to an insulin regulatory locus on chromosome 11 
(Waterworth et al 1997). Whether this represents a common 
genetic defect in PCOS and diabetes or whether it reﬂects 
co-segregation of diabetes with PCOS in the tested families, 
remains to be determined.
Sleep apnea
Sleep apnea is an independent cardiovascular risk factor 
that has been found to be more common in PCOS, the dif-
ference remained signiﬁcant even when controlled for body 
mass index (BMI) (Gopal et al 2002; Fogel et al 2001). It 
was reported that the strongest predictors for sleep apnoea 
were fasting plasma insulin and glucose-to-insulin ratios 
(Vgontzas et al 2001).
Atherosclerosis
The presence of cardiovascular risk factors of obesity, in-
sulin resistance and dyslipidemia may predispose women 
with PCOS to coronary heart disease, although this remains 
controversial:
Angiography
One report evaluated 143 women age less than 60 years old 
undergoing cardiac catheterization for the investigation of Vascular Health and Risk Management 2007:3(1)  58
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chest pain. Polycystic ovarian morphology was present in 
42% of women, and was associated with hirsutism, lower 
levels of HDL cholesterol, and higher concentrations of free 
testosterone, triglyceride, and C-peptide. The women with 
polycystic ovaries had more extensive coronary disease on 
angiography than those with normal ovaries (Birdsall et 
al 1997). However, this study only examined at the asso-
ciation between ultrasound evidence of polycystic ovaries 
alone (rather than the full Rotterdam consensus deﬁnition 
of PCOS) and the extent of coronary disease on cardiac 
catheterization. 
Carotid ultrasound
A predisposition toward atherosclerosis was suggested in an 
ultrasonographic study of 16 women with PCOS aged over 
40 years, where carotid artery intima-media thickness (IMT) 
was signiﬁcantly greater than in normal controls (Guzick et al 
1996). However, the mean IMT in the PCOS group was still 
well below that seen in patients with signiﬁcant carotid artery 
disease. In another study with a larger cohort of subjects, 
the same group of researchers reported that among women 
aged 45 years or above, patients with PCOS had signiﬁcantly 
greater mean carotid IMT than women in the control group 
(Talbott et al 2000).
Endothelial dysfunction 
Endothelial dysfunction is associated with the development 
of atherosclerosis (Celermajer et al 1992). A positive cor-
relation was demonstrated between abnormal endothelial 
function and testosterone levels in hyperandrogenic 
insulin-resistant women with PCOS, an association that was 
stronger than that of insulin sensitivity (Paradisi et al 2001). 
Conversely, others have reported no differences in surrogate 
markers including endothelial function for increased car-
diovascular risk in PCOS compared with weight-matched 
controls (Bickerton et al 2005).
Several mechanisms may be involved in the develop-
ment of endothelial dysfunction, such as reduced synthesis 
and release of nitric oxide (NO) (Kawashima and Yokoyama 
2004), enhanced inactivation of NO after its release from 
endothelial cells (Bitar et al 2005) or enhanced synthesis of 
vasoconstricting agents (Bhagat and Vallance 1999). It has 
been demonstrated that insulin exerts a direct hypertrophic 
effect on the vascular endothelium and the smooth muscle 
cells. It has been found that in the skeletal muscle circulation 
insulin stimulates both endothelin-1 and NO activity, and an 
imbalance between the release of these two substances may 
be involved in the pathophysiology of endothelial dysfunc-
tion. Recent studies suggested that CRP directly promotes the 
atherosclerotic processes and endothelial cell inﬂammation 
leading to atherothrombosis (Sjoholm and Nystrom 2005).
Long-term risk 
In the Nurses’ Health Study, a history of menstrual cycle ir-
regularity was associated with an increased risk of non-fatal 
and fatal coronary heart disease (Solomon et al 2002). This 
might be explained by a high rate of PCOS with its associ-
ated metabolic disturbances in these women, although no 
other clinical or biochemical androgen data was available to 
conﬁrm that menstrual irregularity was due to PCOS.
Despite the increase in cardiovascular risk factors includ-
ing diabetes, hypertension, raised plasma cholesterol and 
BMI >30, morbidity and mortality from of coronary heart 
disease among women with PCOS in a long-term study has 
not proved to be as high as previously predicted (Wild et al 
2000b). 
One recent observation showed no difference in surrogate 
markers of cardiovascular risk between PCOS and weight-
matched controls (glucose, lipid, lipoprotein, sialic acid, ﬁbrino-
gen, CRP, reactive hyperemic forearm blood ﬂow) (Bickerton 
et al 2005). However, in contrast, in another study patients with 
PCOS were found to have elevated triglycerides and cholesterol 
but no differences in CRP or 24 hour BP were observed. In 
addition, they also demonstrated that patients with PCOS had 
increased arterial stiffness measured by pulse wave velocity 
(PWV) and reduced brachial artery ﬂow mediated vasodilatation 
(FMD), a marker of endothelial function (Meyer et al 2005). 
Whether these differences could have been accounted for by 
differing patient selection is unclear.
In summary, cardiovascular disease studies in PCOS 
have been inconclusive with some suggesting increased 
cardiac events among women with PCOS whilst other stud-
ies suggesting no increase compared with normal cycling 
women. This could be due to small sample size in the stud-
ies and variation in the characteristics of patients recruited. 
It has been suggested that patients with PCOS as deﬁned 
by hyperandrogenemia plus either of oligomenorrhoea or 
polycystic ovaries on ultrasound may have a slight increase 
in cardiovascular risk proﬁle as compared with those with 
only oligomenorrhoea and polycystic ovaries without hy-
perandrogenemia.
The role of adipocyte  
in cardiometabolic syndrome
Adipose tissue has traditionally been considered an energy 
storage organ, but over the last decade a novel role of the Vascular Health and Risk Management 2007:3(1)  59
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adipose tissue as an endocrine organ has emerged (Mohamed-
Ali et al 1998; Spiegelman and Flier 1996; Fruhbeck 2004). 
Adipocytes are metabolically active cells which secrete tumor 
necrosis factor alpha, interleukin 6, plasminogen activator 
inhibitor-1, leptin, resistin, adiponectin, and angiotensinogen 
(Rondinone 2006; Yu and Ginsberg 2005).
Leptin is secreted mainly by adipose tissue and deﬁciency 
in leptin results in hyperphagia, decreased energy expenditure 
and morbid obesity (Friedman and Halaas 1998). However, 
in terms of human obesity, leptin deﬁciency is rare. It has 
been postulated that leptin activates the sympathetic nervous 
system and is involved in blood pressure regulation, brain 
and bone development, hematopoiesis and wound healing 
(Ahima and Flier 2000).
It has been suggested that the function of leptin is to control 
the deposition of fat and this modulates its harmful accumulation 
in tissues such as heart, liver and kidneys. Leptin is involved 
in the control of vascular tone by stimutaneously producing a 
pressor action and opposing the nitric oxide mediated relaxing 
function (Fruhbeck and Gomez-Ambrosi 2001). This may 
contribute to the hypertension associated with cardiometabolic 
syndrome. A positive relationship between insulin resistant 
PCOS women (both obese and non-obese) and hyperlep-
tinemia, regardless of the BMI has been suggested in one 
study (Calvar et al 2003).
Increasing adipose tissue mass is associated with increasing 
levels of angiotensin II from the increased secretion of angio-
tensinogen by adipose tissue. Increase in angiotensin II could 
contribute to hypertension and aggravate insulin resistance 
(Engeli et al 2003).
IL-6 inhibits liproprotein lipase activity, enhances aromatase 
activity and increases the hepatic production of triglycerides 
(Nonogaki et al 1995). IL-6 is stimulated by TNF-alpha: TNF 
stimulates C-reactive protein that has been found to be correlated 
with obesity, insulin resistance, endothelial dysfunction, and 
therefore cardiovascular risk, and patients with PCOS have been 
shown to have a higher level of CRP (Kelly et al 2001; Bahceci 
et al 2004). TNF-alpha also suppresses lipoprotein lipase and 
its release is inhibited by the thiazolidinediones and in PCOS, 
serum TNF-alpha is increased irrespective of obesity (Gonzalez 
et al 1999). Elevation of these inﬂammatory markers are in ac-
cord with the hypothesis that atheroma formation is primarily 
an inﬂammatory condition.
Adiponectin is secreted exclusively by adipocytes and 
levels are reduced in obesity, type 2 diabetes and coronary 
heart disease. Studies suggest an important link with insulin 
resistance (Steppan et al 2001) and adiponectin also inhibits 
vascular smooth muscle proliferation and the expression of 
adhesion molecules. Levels of adiponectin are increased by 
weight reduction and by thiazoledinediones (Yu et al 2002). 
It has recently been shown that a signiﬁcant reciprocal cor-
relation exists between adiponectin and resistin independent 
of insulin resistance in women with PCOS (Lewandowski 
et al 2005). Resistin is implicated in the pathogenesis of Type 
2 diabetes and obesity (Seow et al 2004) where circulating 
resistin levels and resistin expression in adipocytes are 
increased. However, the role of resistin in patients with PCOS 
and thus cardiovascular risk in this group is still debatable. In 
one study, serum resistin level in patients with PCOS were 
no different to matched controls but resistin mRNA levels 
were 2-fold higher in omental adipocytes from PCOS patients 
(Seow et al 2004). Others have reported that there is an in-
crease in serum resistin level in patients with PCOS (Munir 
et al 2005), although it has been suggested that this increase 
is dependent on BMI (Panidis et al 2004). Against this ar-
gument is that in BMI matched patients, serum resistin was 
found not to be different compared with controls (Carmina 
et al 2005, 2006). Therefore more studies will be required to 
determine its importance in patients with PCOS.
Therapy of PCOS
The effective treatment of patients with PCOS requires that 
the speciﬁc goal(s) of the therapy be ﬁrst established. Indi-
vidual goals may include fertility, treatment for hirsutism 
and/or acne, achieving a regular menstrual cycle, weight 
reduction, and the prevention of the long-term consequences 
associated with PCOS (type 2 diabetes, dyslipidemia, and 
possibly cardiovascular disease) or all of the above! 
Treatments discussed here will focus on those aimed at 
modifying the cardiometabolic aspects of PCOS.
Exercise and diet
Although obesity is not thought to be the cause for PCOS, 
it may exacerbate this dysfunction (Holte 1996). Loss of 
signiﬁcant weight has been reported to result in spontaneous 
resumption of ovulation (Crosignani et al 2003), improve-
ment in fertility (Norman et al 2004), increased SHBG, and 
reduced basal level of insulin (Huber-Buchholz et al 1999; 
Tolino et al 2005).
Data from the Diabetes Prevention Program (DPP) 
showed the importance of weight reduction in patients 
with impaired glucose tolerance that were at high risk of 
developing diabetes This study showed that both metformin 
therapy and intensive lifestyle intervention reduced the risk 
of developing diabetes (by 31% and 58%, respectively, 
in comparison with placebo), and both interventions were Vascular Health and Risk Management 2007:3(1)  60
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suggested to be cost-effective on the basis of computer pro-
jected lifetime risk (Ratner 2006). In accord with that is the 
observation that signiﬁcant weight loss, ie, >15% of body 
weight, has been found to improve the metabolic proﬁle of 
PCOS women (Kiddy et al 1989).
Insulin sensitizers
Metformin
Metformin is effective in the treatment of metabolic syn-
drome and modestly increases menstrual regularity and 
ovulation, and may improve hirsutism in patients with PCOS 
(Harborne et al 2003). Metformin treatment in lean women 
with PCOS also improves insulin resistance and hyperan-
drogenism without a change in BMI (Nestler and Jakubowicz 
1997). Whilst metformin appears to induce cardio-protective 
effects on serum insulin (Sahin et al 2004), serum lipids 
(Ibanez et al 2004), and PAI-1 (Song et al 2002), the actual 
protection from long-term mortality and morbidity of car-
diovascular disease has yet to be demonstrated. In addition, 
it has been suggested that metformin has a beneﬁcial effect 
on endothelial function in patients with polycystic ovarian 
syndrome (Orio et al 2005).
Thiazolidinediones
Pioglitazone and rosiglitazone have also shown positive 
cardiometabolic effects, reducing hyperandrogenemia, 
and hirsutism as well as regulating the menstrual cycle in 
women with PCOS (Brettenthaler et al 2004; Sepilian and 
Nagamani 2005; Cataldo et al 2006). Rosiglitazone was 
found to markedly reduce liver fat, increase insulin clearance, 
double adiponectin concentrations, and unlike metformin, it 
also increases peripheral insulin sensitivity (Tiikkainen et al 
2004). However, thiazolidinediones causes weight gain that 
may not be a desireable effect in this population of young 
women whose initial presenting complaint may well be the 
inability to lose weight.
Orlistat
Orlistat, a pancreatic lipase inhibitor, limits the absorption 
of dietary fat. We have recently shown that it signiﬁcantly 
reduced body weight and that there was a reduction in total 
testosterone levels in PCOS women equal to that of metfor-
min (Jayagopal et al 2005). In women with PCOS, weight 
loss is associated with an improvement in insulin sensitivity 
and a reduction of the insulin concentration in the plasma 
(Ajossa et al 2004). Therefore weight reduction with orlistat 
would be a suitable adjunct to insulin sensitizers in the treat-
ment of patients with PCOS. 
Sibutamine
Sibutramine, a selective serotonin and adrenergic reuptake 
inhibitor, has shown positive effects on hyperandrogenemia, 
and clinical metabolic risk factors for cardiovascular disease 
in obese women with PCOS (Sabuncu et al 2003). However, 
sibutramine has to be prescribed with care in patients with 
hypertension, and in patients with PCOS, metformin may 
be a more effective treatment in the prompt restoration of 
ovarian function as compared with sibutramine (Lazurova 
et al 2004). 
In summary, cardiovascular disease studies in PCOS 
have been inconclusive, with some suggesting an increased 
in cardiac events among women with PCOS whilst others 
showed no difference. The mainstay of treatment is the 
encouragement of diet and exercise augmented by weight 
reducing medication and use of insulin sensitizers like 
metformin. Insulin sensitisers have beneﬁcial effects on 
menstrual regularity, but their use speciﬁcally for potential 
cardio-protection needs to be clariﬁed.
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